Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Gyre Therapeutics (GYRE) Income towards Parent Company: 2009-2024

Historic Income towards Parent Company for Gyre Therapeutics (GYRE) over the last 16 years, with Dec 2024 value amounting to $16.9 million.

  • Gyre Therapeutics' Income towards Parent Company rose 107.84% to $5.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.8 million, marking a year-over-year increase of 112.80%. This contributed to the annual value of $16.9 million for FY2024, which is 119.58% up from last year.
  • Per Gyre Therapeutics' latest filing, its Income towards Parent Company stood at $16.9 million for FY2024, which was up 119.58% from -$86.3 million recorded in FY2023.
  • Gyre Therapeutics' 5-year Income towards Parent Company high stood at $16.9 million for FY2024, and its period low was -$87.9 million during FY2021.
  • Over the past 3 years, Gyre Therapeutics' median Income towards Parent Company value was $3.4 million (recorded in 2022), while the average stood at -$22.0 million.
  • In the last 5 years, Gyre Therapeutics' Income towards Parent Company tumbled by 2,620.85% in 2023 and then surged by 119.58% in 2024.
  • Gyre Therapeutics' Income towards Parent Company (Yearly) stood at -$56.3 million in 2020, then crashed by 56.10% to -$87.9 million in 2021, then soared by 103.89% to $3.4 million in 2022, then tumbled by 2,620.85% to -$86.3 million in 2023, then skyrocketed by 119.58% to $16.9 million in 2024.